Yahoo! Finance: Biotechnology Industry News: Dendreon Grasps for Bid as Main Drug Burns Cash: Real M&A

Yahoo! Finance: Biotechnology Industry News The latest news on the Biotechnology industry from Yahoo! Finance

Subscribe to Bloomberg Businessweek Get Bloomberg Businessweek for 84% off what others pay on the newsstand - that's like getting 38 complimentary issues! Sign up today. From our sponsors

Dendreon Grasps for Bid as Main Drug Burns Cash: Real M&A Oct 30th 2013, 02:44 [at Bloomberg] - Dendreon Corp. is facing an uphill battle in its search for a buyer willing to take on the steep expenses and disappointing sales growth of its prostate-cancer drug Provenge.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions